Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 3:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate to Severe Rheumatoid Arthritis Clear all
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis

NCT00106574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
76
States / cities
Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 3:32 AM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
View directory record Official record
Conditions
Sjögren's Syndrome (SS)
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
41
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 23, 2026, 3:32 AM EDT
Terminated Phase 4 Interventional Results available

A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor

NCT01283971
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], adalimumab, placebo to tocilizumab, placebo to adalimumab, methotrexate, folate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
107
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 95 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2014 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

NCT04247815
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ATI-450, Placebo oral tablet, Methotrexate
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Anniston, Alabama • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Jul 23, 2026, 3:32 AM EDT
Terminated Phase 3 Interventional Results available

A Study in Participants With Rheumatoid Arthritis

NCT01202773
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2127399, Placebo Q4W, Placebo Q2W
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Paradise Valley, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

NCT05848258
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY3871801, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Huntington Beach, California • Doral, Florida • Ocoee, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy

NCT00106522
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Placebo, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
97
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT05516758
View directory record Official record
Conditions
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Peresolimab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Gilbert, Arizona • Glendale, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 23, 2026, 3:32 AM EDT
Not listed Phase 2 Interventional

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

NCT01408602
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MRC375, Matching Placebo, MRC375 150mg
Drug
Lead sponsor
Molecular Research Center, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
19
States / cities
Mobile, Alabama • Long Beach, California • Los Alamitos, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 11, 2014 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Jul 23, 2026, 3:32 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)

NCT06041269
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rosnilimab, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
36
States / cities
Flagstaff, Arizona • Glendale, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

NCT02057250
View directory record Official record
Conditions
RA
Interventions
Sarilumab, Auto-Injector Device (AID), Pre-filled Syringe (PFS), Methotrexate, Sulfasalazine, Leflunomide, Hydroxychloroquine
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
31
States / cities
Huntsville, Alabama • Peoria, Arizona • Roseville, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis

NCT00535782
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
26
States / cities
Anniston, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).

NCT02480153
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, Adalimumab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
49
States / cities
Gilbert, Arizona • Glendale, Arizona • Phoenix, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis

NCT00109408
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, tocilizumab [RoActemra/Actemra]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
70
States / cities
Montgomery, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jul 23, 2026, 3:32 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Lutikizumab, Placebo, Ravagalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
56
States / cities
Peoria, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 1 Interventional

Therapeutic Response of Cannabidiol in Rheumatoid Arthritis

NCT04911127
View directory record Official record
Conditions
Rheumatoid Arthritis, Cannabis
Interventions
200mg Cannabidiol by capsules twice daily, 400mg Cannabidiol by capsules twice daily, Placebo capsules
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Jul 23, 2026, 3:32 AM EDT
Terminated Phase 2 Interventional Results available

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

NCT02862574
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Andecaliximab, Placebo, Methotrexate, TNF Inhibitor
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Palo Alto, California • DeBary, Florida • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers

NCT03315494
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
SKI-O-703 capsule, Placebo capsule
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Long-Term Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) in Patients Who Require Opioid Treatment for an Extended Period of Time

NCT01223365
View directory record Official record
Conditions
Chronic Pain
Interventions
Hydrocodone ER
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
54
States / cities
Mobile, Alabama • Anaheim, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

NCT05198310
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
KPL-404, Placebo
Drug
Lead sponsor
Kiniksa Pharmaceuticals, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Apple Valley, California • Covina, California • Upland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jul 23, 2026, 3:32 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate

NCT02706873
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,002 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
32
States / cities
La Mesa, California • Palm Desert, California • Daytona Beach, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jul 23, 2026, 3:32 AM EDT